SPY468.28+9.49 2.07%
DIA357.74+4.92 1.39%
IXIC15,686.92+461.76 3.03%

Ginkgo Bioworks Launches Cell Development Kit Service For Standardized, Low-Cost Entry To Its Cell Programming Platform

Ginkgo Bioworks (NYSE:DNA), the leading horizontal platform for cell programming, today announced the launch of its Cell Development Kits (CDKs) service. CDKs provide streamlined access to the company's platform

Benzinga · 11/11/2021 07:05

Ginkgo Bioworks (NYSE:DNA), the leading horizontal platform for cell programming, today announced the launch of its Cell Development Kits (CDKs) service. CDKs provide streamlined access to the company's platform for aspiring cell developers to program cells to tackle the biggest challenges facing society. The first CDKs to launch are focused on protein expression programs. The service provides developers access to the toolkit needed to get started developing commercial proteins, including pre-engineered host cells optimized for protein production, specialized equipment, automation capabilities, genetic engineering expertise, insights garnered from Ginkgo's codebase and the applicable infrastructure to design, build and test a custom microbe.